Brandon K Bellows1, Natalia Ruiz-Negrón2,3, Kirsten Bibbins-Domingo4, Jordan B King5, Mark J Pletcher4, Andrew E Moran1, Valy Fontil6. 1. Columbia University, Division of General Medicine, New York, NY (B.K.B., A.E.M.). 2. University of Utah, Department of Pharmacotherapy, Salt Lake City, UT (N.R.-N.). 3. SelectHealth, Murray, UT (N.R.-N.). 4. Department of Epidemiology and Biostatistics, University of California at San Francisco (K.B.-D., M.J.P.). 5. Department of Population Health Sciences, University of Utah, Salt Lake City, UT (J.B.K.). 6. Division of General Medicine, University of California at San Francisco (V.F.).
Abstract
BACKGROUND: The Centers for Disease Control and Prevention's Million Hearts initiative includes an ambitious ≥80% blood pressure control goal in US adults with hypertension by 2022. We used the validated Blood Pressure Control Model to quantify changes in clinic-based hypertension management processes needed to attain ≥80% blood pressure control. METHODS AND RESULTS: The Blood Pressure Control Model simulates patient blood pressures weekly using 3 key modifiable hypertension management processes: office visit frequency, clinician treatment intensification given uncontrolled blood pressure, and continued antihypertensive medication use (medication adherence rate). We compared blood pressure control rates (using the Seventh Joint National Committee on hypertension targets) achieved over 4 years between usual care and the best-observed values for management processes identified from the literature (1-week return visit interval, 20%-44% intensification rate, and 76% adherence rate). We determined the management process values needed to achieve ≥80% blood pressure control in US adults. In adults with uncontrolled blood pressure, usual care achieved 45.6% control (95% uncertainty interval, 39.6%-52.5%) and literature-based best-observed values achieved 79.7% control (95% uncertainty interval, 79.3%-80.1%) over 4 years. Increasing treatment intensification rates to 62% of office visits with an uncontrolled blood pressure resulted in ≥80% blood pressure control, even when the return visit interval and adherence remained at usual care values. Improving to best-observed values for all 3 management processes would achieve 78.1% blood pressure control in the overall US population with hypertension, approaching the ≥80% Million Hearts 2022 goal. CONCLUSIONS: Achieving the Million Hearts blood pressure control goal by 2022 will require simultaneously increasing visit frequency, overcoming therapeutic inertia, and improving patient medication adherence. As the relative importance of each of these 3 processes will depend on local characteristics, simulation models like the Blood Pressure Control Model can help local healthcare systems tailor strategies to reach local and national benchmarks.
BACKGROUND: The Centers for Disease Control and Prevention's Million Hearts initiative includes an ambitious ≥80% blood pressure control goal in US adults with hypertension by 2022. We used the validated Blood Pressure Control Model to quantify changes in clinic-based hypertension management processes needed to attain ≥80% blood pressure control. METHODS AND RESULTS: The Blood Pressure Control Model simulates patient blood pressures weekly using 3 key modifiable hypertension management processes: office visit frequency, clinician treatment intensification given uncontrolled blood pressure, and continued antihypertensive medication use (medication adherence rate). We compared blood pressure control rates (using the Seventh Joint National Committee on hypertension targets) achieved over 4 years between usual care and the best-observed values for management processes identified from the literature (1-week return visit interval, 20%-44% intensification rate, and 76% adherence rate). We determined the management process values needed to achieve ≥80% blood pressure control in US adults. In adults with uncontrolled blood pressure, usual care achieved 45.6% control (95% uncertainty interval, 39.6%-52.5%) and literature-based best-observed values achieved 79.7% control (95% uncertainty interval, 79.3%-80.1%) over 4 years. Increasing treatment intensification rates to 62% of office visits with an uncontrolled blood pressure resulted in ≥80% blood pressure control, even when the return visit interval and adherence remained at usual care values. Improving to best-observed values for all 3 management processes would achieve 78.1% blood pressure control in the overall US population with hypertension, approaching the ≥80% Million Hearts 2022 goal. CONCLUSIONS: Achieving the Million Hearts blood pressure control goal by 2022 will require simultaneously increasing visit frequency, overcoming therapeutic inertia, and improving patient medication adherence. As the relative importance of each of these 3 processes will depend on local characteristics, simulation models like the Blood Pressure Control Model can help local healthcare systems tailor strategies to reach local and national benchmarks.
Authors: Boris L G van Wijk; William H Shrank; Olaf H Klungel; Sebastian Schneeweiss; M Alan Brookhart; Jerry Avorn Journal: J Hypertens Date: 2008-01 Impact factor: 4.844
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti Journal: Lancet Date: 2004-06-19 Impact factor: 79.321
Authors: Shari Danielle Bolen; T Alafia Samuels; Hsin-Chieh Yeh; Spyridon S Marinopoulos; Maura McGuire; Marcela Abuid; Frederick L Brancati Journal: J Gen Intern Med Date: 2008-01-25 Impact factor: 5.128
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: Catherine G Derington; Jordan B King; Kelsey B Bryant; Blake T McGee; Andrew E Moran; William S Weintraub; Brandon K Bellows; Adam P Bress Journal: Curr Hypertens Rep Date: 2019-11-07 Impact factor: 5.369
Authors: Paul Muntner; Shakia T Hardy; Lawrence J Fine; Byron C Jaeger; Gregory Wozniak; Emily B Levitan; Lisandro D Colantonio Journal: JAMA Date: 2020-09-22 Impact factor: 56.272
Authors: Jeffrey W Brettler; Gloria P Giraldo Arcila; Teresa Aumala; Allana Best; Norm Rc Campbell; Shana Cyr; Angelo Gamarra; Marc G Jaffe; Mirna Jimenez De la Rosa; Javier Maldonado; Carolina Neira Ojeda; Modesta Haughton; Taraleen Malcolm; Vivian Perez; Gonzalo Rodriguez; Andres Rosende; Yamile Valdes Gonzalez; Peter W Wood; Eric Zuniga; Pedro Ordunez Journal: Rev Panam Salud Publica Date: 2022-05-10
Authors: Alexander R Zheutlin; Catherine G Derington; Jordan B King; Ransmond O Berchie; Jennifer S Herrick; Dave L Dixon; Jordana B Cohen; Daichi Shimbo; Ian M Kronish; Joseph J Saseen; Paul Muntner; Andrew E Moran; Adam P Bress Journal: Am Heart J Date: 2021-10-16 Impact factor: 5.099
Authors: Kelsey B Bryant; Andrew E Moran; Dhruv S Kazi; Yiyi Zhang; Joanne Penko; Natalia Ruiz-Negrón; Pamela Coxson; Ciantel A Blyler; Kathleen Lynch; Laura P Cohen; Gabriel S Tajeu; Valy Fontil; Norma B Moy; Joseph E Ebinger; Florian Rader; Kirsten Bibbins-Domingo; Brandon K Bellows Journal: Circulation Date: 2021-04-15 Impact factor: 39.918
Authors: Alexander R Zheutlin; Favel L Mondesir; Catherine G Derington; Jordan B King; Chong Zhang; Jordana B Cohen; Dan R Berlowitz; D Edmund Anstey; William C Cushman; Tom H Greene; Olugbenga Ogedegbe; Adam P Bress Journal: JAMA Netw Open Date: 2022-01-04
Authors: Kelsey B Bryant; James P Sheppard; Natalia Ruiz-Negrón; Ian M Kronish; Valy Fontil; Jordan B King; Mark J Pletcher; Kirsten Bibbins-Domingo; Andrew E Moran; Richard J McManus; Brandon K Bellows Journal: J Am Heart Assoc Date: 2020-07-22 Impact factor: 5.501